# Immunotherapy for Solid Tumor Malignancies in Pediatrics Using Interleukin-15 and -21 Armored Glypican-3-specific Chimeric Antigen Receptor T Cells

> **NCT07148050** · PHASE1 · RECRUITING · sponsor: **Seattle Children's Hospital** · enrollment: 21 (estimated)

## Conditions studied

- Solid Tumor (Excluding CNS)
- Liver Cell Carcinoma
- Malignant Rhabdoid Tumor
- Yolk Sac Tumor
- Liposarcoma
- Rhabdomyosarcoma
- Embryonal Sarcoma of Liver
- Wilms Tumor
- Hepatocellular Carcinoma
- Hepatoblastoma

## Interventions

- **BIOLOGICAL:** SC-CAR.GPC3xIL15.21 CAR T cells

## Key facts

- **NCT ID:** NCT07148050
- **Lead sponsor:** Seattle Children's Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-12-22
- **Primary completion:** 2029-04-22
- **Final completion:** 2044-04-22
- **Target enrollment:** 21 (ESTIMATED)
- **Last updated:** 2026-02-17


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07148050

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07148050, "Immunotherapy for Solid Tumor Malignancies in Pediatrics Using Interleukin-15 and -21 Armored Glypican-3-specific Chimeric Antigen Receptor T Cells". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT07148050. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*